GlassScriptPhysician profile
Hailey N Ray
NPI 1598350423
$7,374.42
in general payments reported to CMS, 2019-2025
55 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $751 · 2023: $1,058 · 2024: $2,672 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944 · Long Term Medical Supply Or Device Loan: $2,180 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.35 |
| Long Term Medical Supply Or Device Loan | $2,179.99 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,723.09 | 2022-2025 | |
| Janssen Biotech, INC. | $656.72 | 2021-2025 | Rybrevant, Akeega, Erleada |
| Seagen INC. | $390.08 | 2021-2023 | Tukysa |
| Gilead Sciences, INC. | $334.76 | 2022-2025 | Trodelvy |
| Amgen INC. | $246.31 | 2021-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $216.24 | 2021-2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $209.04 | 2021-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $182.01 | 2021-2025 | Phesgo, Tecentriq, Perjeta |
| Incyte Corporation | $172.78 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $133.72 | 2023-2025 | |
| Eisai INC. | $119.16 | 2024-2025 | |
| Daiichi Sankyo INC. | $118.46 | 2022-2025 | Enhertu, Injectafer |
| Caris Mpi, INC. | $113.12 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $107.71 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $104.78 | 2023-2025 | Tepmetko |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $104.56 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $101.65 | 2023-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $84.90 | 2021-2024 | Onivyde |
| Astellas Pharma US INC | $83.18 | 2022-2025 | Cresemba, Xospata |
| Servier Pharmaceuticals LLC | $75.46 | 2024-2025 | |
| Taiho Oncology, INC. | $67.65 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.60 | 2023-2024 | Alunbrig, Iclusig, Ninlaro |
| Abbvie INC. | $62.20 | 2022-2025 | |
| Puma Biotechnology, INC. | $47.92 | 2021-2023 | Nerlynx |
| Genzyme Corporation | $47.46 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.44 | 2022-2023 | |
| Exelixis INC. | $43.90 | 2021-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $43.58 | 2022-2025 | Xpovio |
| Celgene Corporation | $39.63 | 2022-2024 | Reblozyl |
| Sun Pharmaceutical Industries INC. | $39.41 | 2022-2023 | Yonsa, Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.08 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $34.91 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Deciphera Pharmaceuticals INC. | $32.86 | 2022-2025 | Romvimza, Qinlock |
| Alnylam Pharmaceuticals INC. | $32.54 | 2022-2023 | Amvuttra |
| Genentech, INC. | $32.38 | 2025 | Itovebi |
| Adaptive Biotechnologies Corporation | $31.62 | 2023-2024 | Clonoseq |
| Tempus Ai, INC | $29.44 | 2024 | Xt Cdx |
| Mirati Therapeutics, INC. | $29.35 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $28.86 | 2023-2024 | Monoferric |
| Blueprint Medicines Corporation | $23.42 | 2025 | Ayvakit |
| Immunocore Limited | $22.09 | 2023 | Kimmtrak |
| Array Biopharma INC | $22.08 | 2025 | Lorbrena, Braftovi, Mektovi |
| Geron Corporation | $21.31 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $20.92 | 2025 | Orserdu |
| Acrotech Biopharma INC. | $20.57 | 2023 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $19.78 | 2022 | |
| Boston Scientific Corporation | $19.73 | 2024 | Spaceoar Vue System - 10ml |
| Agios Pharmaceuticals, INC. | $19.53 | 2025 | Pyrukynd |
| Tg Therapeutics, INC. | $18.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.15 | 2022 | |
| G1 Therapeutics, INC. | $17.03 | 2022 | |
| Beigene USA, INC. | $16.95 | 2024 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $16.18 | 2024 | Myrisk |
| Azurity Pharmaceuticals, INC. | $14.08 | 2025 | Vivimusta, Danziten |
| Coherus Oncology, INC. | $13.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.